Toxicological evaluation of some food additives including anticaking agents, antimicrobials, antioxidants, emulsifiers and thickening agents WHO FOOD ADDITIVES SERIES NO. 5 The evaluations contained in this publication were prepared by the Joint FAO/WHO Expert Committee on Food Additives which met in Geneva, 25 June - 4 July 19731 World Health Organization Geneva 1974 1 Seventeenth Report of the Joint FAO/WHO Expert Committee on Food Additives, Wld Hlth Org. techn. Rep. Ser., 1974, No. 539; FAO Nutrition Meetings Report Series, 1974, No. 53. TARTARIC ACID AND ITS POTASSIUM, POTASSIUM-SODIUM AND SODIUM SALTS Explanation These compounds have been evaluated for acceptable daily intake by the Joint FAO/WHO Expert Committee on Food Additives (see Annex 1, Refs Nos. 6, 7 and 8) in 1961, 1963 and 1964. Since the previous evaluation, additional data have become available and are summarized and discussed in the following monograph. The previously published monographs have been expanded and are reproduced in their entirety below. BIOLOGICAL DATA BIOCHEMICAL ASPECTS Tartaric acid is metabolically inert in the human body (Underhill et al., 1931a, b, c; Finkle, 1933). When taken by mouth, only about 20% of ingested tartrate is eliminated in the urine; the remainder is not absorbed as such since it is destroyed in the intestinal tract by bacterial action. Sodium tartrate in daily doses of up to 10 or even 20 g has been used in medical practice as a laxative. It has been tested for this action in a clinical study involving the application of daily doses of 10 g of sodium tartrate to 26 patients for an average of 11.8 doses, giving laxative responses in 66% of the subjects. The only side effects noticed were nausea or vomiting (1.6%) and abdominal cramps (2.1%). Renal damage has been observed only after the intravenous administration of tartaric acid in doses of 0.2 to 0.3 g in rabbits and rats (Bodansky et al., 1942; Gold & Zahm, 1943). TOXICOLOGICAL STUDIES Acute toxicity In the mouse, the LD50 of the sodium salt administered by mouth was found to be 4360 mg/kg bw (Locke et al., 1942). Tartaric acid administered by stomach tube in a dose of 5000 mg/ kg was fatal to a dog (Sourkes & Koppanyi, 1950). Three out of seven male rabbits died following oral administration of disodium tartrate in an average dose of 5290 mg/kg; while six male rabbits survived an average oral dose of 3680 mg/kg (Locke et al., 1942). Short-term studies Rabbit Three rabbits survived 17 consecutive daily feedings of disodium tartrate in an average dosage of 1150 mg/kg; whereas average dosages of 3680 mg/kg killed three out of six rabbits in six to 19 consecutive daily feedings (Locke et al., 1942). Dog Tartaric acid was administered in daily oral doses of 990 mg/kg to each of four dogs for 90 to 114 days. Casts appeared in the urine of three dogs; the blood chemistry remained normal except in one dog in which azotaemia developed with death in 90 days. Weight changes varied from a gain of 30% to a loss of 32% (Krop & Gold, 1945). Long-term studies Rat Groups of 24 rats (12 of each sex) were fed diets containing 0.1%, 0.5%, 0.8% and 1.2% of tartaric acid for a period of two years. A group of 48 rats served as controls. No significant toxic effects were observed in any of the groups as determined by growth rate (for the first year), mortality throughout the experiment, and gross and microscopic findings at the end of the two-year period. An exceptionally thorough microscopic pathological examination was carried out (Fitzhugh & Nelson, 1947). Comments: The long-term study in rats showed no adverse effects at the highest level tested and they have been used medicinally for long periods. The evaluation is, therefore, based on the metabolic inertness of three tartrates and the fact that they are normal constituents of food. EVALUATION Estimate of acceptable daily intake for man 0-30* mg/kg bw. * Calculated as L(+)-tartaric acid. REFERENCES Bodansky, O., Gold, H. & Zahm, W. (1942) J. Amer. pharm. Ass,, sci. Ed., 31, 1 Finkle, P. (1933) J. biol. Chem., 100, 349 Fitzhugh, O, G. & Nelson, A. A. (1947) J. Amer. pharm. Ass., sci. Ed., 36, 217 Gold, H. & Zahm, W. (1943) J. Amer. pharm. Ass., sci. Ed., 32, 173 Krop, S. & Gold, H. (1945) J. Amer. pharm. Ass., sci. Ed., 34, 86 Locke, A., Locke, R. B., Schlesinger, H. & Carr, H. (1942) J. Amer. pharm. Ass., sci. Ed., 31, 12 Sourkes, T. L. & Koppanyi, T. (1950) J. Amer. pharm. Ass., sci. Ed., 39, 275 Underhill, F. P., Leonard, C. S., Gross, E. G. & Joleski, T. C. (1931b) J. Pharmacol. exp. Ther., 43, 359 Underhill, F. P., Peterman F. I., Joleski, T. C. & Leonard, C. S. (1931c) J. Pharmacol. exp. Ther., 43, 381 Underhill, F. P., Peterman, F. I. & Krause, A. G. (1931a) J. Pharmacol. exp. Ther., 43, 351
See Also: Toxicological Abbreviations